|
151 |
Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study |
Healey JS, Oldgren J, Ezekowitz M, Zhu J, Pais P, Wang J, Commerford P, Jansky P, Avezum A, Sigamani A, Demasceno A, Reilly P, Grinvalds A, Nakamya J, Aje A, Almahmeed W, Moriarty A, Wallentin L, Yusuf S, Connolly SJ |
Lancet |
2016 |
|
152 |
Age-specific and sex-specific adult mortality risk in India in 2014: analysis of 0·27 million nationally surveyed deaths and demographic estimates from 597 districts |
Ram U, Jha P, Gerland P, Hum RJ, Rodriguez P, Suraweera W, Kumar K, Kumar R, Dikshit R, Xavier D, Gupta R, Gupta PC, Ram F |
Lancet Glob Health |
2015 |
|
153 |
High sensitivity C-reactive protein (hsCRP) & cardiovascular disease: An Indian perspective |
Kamath DY, Xavier D, Sigamani A, Pais P |
Indian J Med Res |
2015 |
|
154 |
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial |
Granger CB, Lopes RD, Hanna M, Ansell J, Hylek EM, Alexander JH, Thomas L, Wang J, Bahit MC, Verheugt F, Lawrence J, Xavier D, Wallentin L |
Am Heart J |
2015 |
|
155 |
Prevalence, treatments and outcomes of coronary artery disease in Indians: A systematic review |
Rao M, Xavier D, Devi P, Sigamani A, Faruqui A, Gupta R, Kerkar P, Jain RK, Joshi R, Chidambaram N, Rao DS, Thanikachalam S, Iyengar SS, Verghese K, Mohan V, Pais P |
Indian Heart J |
2015 |
|
156 |
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial |
Christopher B. Granger, Renato D. Lopes, Michael Hanna, Jack Ansell, Elaine M. Hylek, John H. Alexander, Laine Thomas, Junyuan Wang, M. Cecilia Bahit, Freek Verheug, Jack Lawrence, *Denis Xavier*, Lars Wallentin. |
American Heart Journal January |
2015 |
|
157 |
Physicians Perception on Complementary and Alternative Medicine (CAM): A Cross Sectional Survey at Tertiary Care Hospital in India |
NS Kunnoor, R Rathore, *D Xavier* |
Medicinal chemistry |
2015 |
|
158 |
Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics |
Eva Lonn, Jackie Bosch, Janice Pogue, Alvaro Avezum, *Prem Pais*, *Denis Xavier*, Salim Yusuf, et al. |
Canadian Journal of Cardiology |
2015 |
|
159 |
Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease |
Avezum A,Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, *Pais P*, Erol C, Diaz R, Bahit MC, Bartunek J, Caterina RD, Goto S, Ruzyllo W, Zhu J, Granger CB & Alexander JH. |
Circulation |
2015 |
|
160 |
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial |
Alexander JH, Lopes RD, Thomas L, Alings M, Atar D, Aylward P, Goto S, Hanna M, Huber K, Husted S, Lewis BS, McMurray JJ, Pais P, Pouleur H, Steg PG, Verheugt FW, Wojdyla DM, Granger CB, Wallentin L |
Eur Heart J |
2014 |
|
161 |
Rationale and design of a randomized controlled trial evaluating community health worker-based interventions for the secondary prevention of acute coronary syndromes in India (SPREAD) |
Kamath DY, Xavier D, Gupta R, Devereaux PJ, Sigamani A, Hussain T, Umesh S, Xavier F, Girish P, George N, Thomas T, Chidambaram N, Joshi R, Pais P, Yusuf S |
Am Heart J |
2014 |
|
162 |
Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)Trial |
Goto S, Zhu J, Liu L, Oh BH, Wojdyla DM, Aylward P, Bahit MC, Gersh BJ, Hanna M, Horowitz J, Lopes RD, Wallentin L, Xavier D, Alexander JH; ARISTOTLE Investigators |
Am Heart J |
2014 |
|
163 |
Management of NCD in Low- and Middle-Income Countries |
Checkley W, Ghannem H, Irazola V, Kimaiyo S, Levitt NS, Miranda JJ, Niessen L, Prabhakaran D, Rabadán-Diehl C, Ramirez-Zea M, Rubinstein A, Sigamani A, Smith R, Tandon N, Wu Y, Xavier D, Yan LL |
Glob Heart |
2014 |
|
164 |
Management and clinical outcomes in patients treated with apixaban versus warfarin undergoing procedures |
Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, Al-Khatib SM, Dorian P, Ansell J, Commerford P, Flaker G, Lanas F, Vinereanu D, Xavier D, Hylek EM, Held C, Verheugt FW, Granger CB, Lopes RD |
Blood |
2014 |
|
165 |
Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes |
Botto F, Alonso-Coello P, Chan MT, Villar JC, Xavier D, et al |
Anesthesiology |
2014 |